Market Overview:
The global rivaroxaban API market is expected to grow at a CAGR of XX% during the forecast period from 2018 to 2030. The market growth can be attributed to the increasing prevalence of thromboembolic disorders, rising geriatric population, and growing demand for novel anticoagulants. However, the high cost of novel anticoagulants may restrain the growth of this market in some regions. The global rivaroxaban API market is segmented on the basis of type and application.
Product Definition:
API is an abbreviation for "Application Programming Interface." An API is a set of programming instructions and protocols that allow software to interact with other software. Rivaroxaban API refers to the application programming interface for the drug rivaroxaban. This API allows developers to create software that can interact with rivaroxaban, making it easier for doctors and patients to access information about the drug and its use. The importance of Rivaroxaban's API lies in its ability to make it easier for people to use rivaroxaban, which could lead to more widespread adoption of the drug as a treatment option.
Purity≥98%:
Rivaroxaban is a blood thinner and has anticoagulant properties. It's major application includes prevention of blood clotting after an injury or surgery. The drug’s mechanism of action involves inhibition of vitamin K epoxide reductase complex, which leads to reduced production of pro-thrombin by the liver. Rivaroxaban was approved by the U.
Purity
Rivaroxaban is a blood thinner and has anticoagulant properties. It is used in the treatment of deep vein thrombosis (DVT), pulmonary embolism (PE), and to prevent the occurrence of DVT and PE during surgery. The product also displays anti-platelet activity, which makes it useful for prevention as well as treatment of heart-related diseases such as coronary artery disease, congestive heart failure, etc.
Application Insights:
Rivaroxaban tablets were the largest revenue-generating segment in 2017. It is used for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE). The growing usage of rivaroxaban tablets for the treatment of various diseases, such as PE and DVT, is expected to drive its demand over the forecast period. In addition, it also has a high preference as an anticoagulant in open heart surgery which further supports its demand over the forecast period.
Rising awareness about blood clots among individuals susceptible to their development due to conditions such as atrial fibrillation or other risk factors including smoking and obesity are anticipated to boost rivaroxaban API market growth during future years. Furthermore, increasing research & development initiatives by key industry players coupled with favorable government regulations will further propel market growth during future years.
Regional Analysis:
North America dominated the global market in 2017 owing to the presence of key players and high patient awareness levels coupled with relatively higher healthcare expenditure. The U.S.
Asia Pacific is anticipated to witness lucrative growth over the forecast period owing to rising disposable income levels, improving economic conditions especially in developing countries such as India & China which are expected lead rivaroxaban API exports from these countries over the forecast period. Rivaroxaban was launched by Sun Pharmaceutical Industries Ltd., India under trade name Xarelto in September 2015 followed by Bayer AG with Eliquis drug product launch in March 2016; both were indicated for acute coronary syndrome (ACS) patients unresponsive to conventional therapy including aspirin and other antiplatelet drugs (coumarin derivatives).
Growth Factors:
- Increasing incidence of thromboembolic disorders: Rivaroxaban API is used for the prevention and treatment of thromboembolic disorders. The increasing incidence of these disorders is expected to drive the growth of the Rivaroxaban API market.
- Growing demand for novel anticoagulants: The growing demand for novel anticoagulants is another key factor that is expected to drive the growth of the Rivaroxaban API market in the coming years.
- Rising geriatric population: The global geriatric population is increasing at a rapid pace, which in turn is leading to an increase in cases of thromboembolic disorders. This will create a high demand for Rivaroxaban APIs in the coming years.
Scope Of The Report
Report Attributes
Report Details
Report Title
Rivaroxaban API Market Research Report
By Type
Purity≥98%, Purity<98%
By Application
Rivaroxaban Tablets, Others
By Companies
Dr. Reddy's Laboratories, Actis Generics Pvt Ltd., ZCL Chemicals Limited, Medichem S.A, UQUIFA, Inke, Teva Pharmaceutical Industries Ltd., Zhejiang Huahai Pharmaceutial. Co., Ltd., Morepen Labs, Shaanxi Hanjiang Pharmaceutical, Jiangsu Jiayi, Shanghai Haoyuan, Nanjing Hicin
Regions Covered
North America, Europe, APAC, Latin America, MEA
Base Year
2021
Historical Year
2019 to 2020 (Data from 2010 can be provided as per availability)
Forecast Year
2030
Number of Pages
223
Number of Tables & Figures
157
Customization Available
Yes, the report can be customized as per your need.
Global Rivaroxaban API Market Report Segments:
The global Rivaroxaban API market is segmented on the basis of:
Types
Purity≥98%, Purity<98%
The product segment provides information about the market share of each product and the respective CAGR during the forecast period. It lays out information about the product pricing parameters, trends, and profits that provides in-depth insights of the market. Furthermore, it discusses latest product developments & innovation in the market.
Applications
Rivaroxaban Tablets, Others
The application segment fragments various applications of the product and provides information on the market share and growth rate of each application segment. It discusses the potential future applications of the products and driving and restraining factors of each application segment.
Some of the companies that are profiled in this report are:
- Dr. Reddy's Laboratories
- Actis Generics Pvt Ltd.
- ZCL Chemicals Limited
- Medichem S.A
- UQUIFA
- Inke
- Teva Pharmaceutical Industries Ltd.
- Zhejiang Huahai Pharmaceutial. Co., Ltd.
- Morepen Labs
- Shaanxi Hanjiang Pharmaceutical
- Jiangsu Jiayi
- Shanghai Haoyuan
- Nanjing Hicin
Highlights of The Rivaroxaban API Market Report:
- The market structure and projections for the coming years.
- Drivers, restraints, opportunities, and current trends of market.
- Historical data and forecast.
- Estimations for the forecast period 2030.
- Developments and trends in the market.
- By Type:
- Purity≥98%
- Purity<98%
- By Application:
- Rivaroxaban Tablets
- Others
- Market scenario by region, sub-region, and country.
- Market share of the market players, company profiles, product specifications, SWOT analysis, and competitive landscape.
- Analysis regarding upstream raw materials, downstream demand, and current market dynamics.
- Government Policies, Macro & Micro economic factors are also included in the report.
We have studied the Rivaroxaban API Market in 360 degrees via. both primary & secondary research methodologies. This helped us in building an understanding of the current market dynamics, supply-demand gap, pricing trends, product preferences, consumer patterns & so on. The findings were further validated through primary research with industry experts & opinion leaders across countries. The data is further compiled & validated through various market estimation & data validation methodologies. Further, we also have our in-house data forecasting model to predict market growth up to 2030.
Regional Analysis
- North America
- Europe
- Asia Pacific
- Middle East & Africa
- Latin America
Note: A country of choice can be added in the report at no extra cost. If more than one country needs to be added, the research quote will vary accordingly.
The geographical analysis part of the report provides information about the product sales in terms of volume and revenue in regions. It lays out potential opportunities for the new entrants, emerging players, and major players in the region. The regional analysis is done after considering the socio-economic factors and government regulations of the countries in the regions.
How you may use our products:
- Correctly Positioning New Products
- Market Entry Strategies
- Business Expansion Strategies
- Consumer Insights
- Understanding Competition Scenario
- Product & Brand Management
- Channel & Customer Management
- Identifying Appropriate Advertising Appeals
8 Reasons to Buy This Report
- Includes a Chapter on the Impact of COVID-19 Pandemic On the Market
- Report Prepared After Conducting Interviews with Industry Experts & Top Designates of the Companies in the Market
- Implemented Robust Methodology to Prepare the Report
- Includes Graphs, Statistics, Flowcharts, and Infographics to Save Time
- Industry Growth Insights Provides 24/5 Assistance Regarding the Doubts in the Report
- Provides Information About the Top-winning Strategies Implemented by Industry Players.
- In-depth Insights On the Market Drivers, Restraints, Opportunities, and Threats
- Customization of the Report Available
Frequently Asked Questions?
Rivaroxaban is an oral anticoagulant medication used to prevent blood clots.
Some of the major players in the rivaroxaban api market are Dr. Reddy's Laboratories, Actis Generics Pvt Ltd., ZCL Chemicals Limited, Medichem S.A, UQUIFA, Inke, Teva Pharmaceutical Industries Ltd., Zhejiang Huahai Pharmaceutial. Co., Ltd., Morepen Labs, Shaanxi Hanjiang Pharmaceutical, Jiangsu Jiayi, Shanghai Haoyuan, Nanjing Hicin.
Chapter 1 Executive Summary
Chapter 2 Assumptions and Acronyms Used
Chapter 3 Research Methodology
Chapter 4 Rivaroxaban API Market Overview
4.1 Introduction
4.1.1 Market Taxonomy
4.1.2 Market Definition
4.1.3 Macro-Economic Factors Impacting the Market Growth
4.2 Rivaroxaban API Market Dynamics
4.2.1 Market Drivers
4.2.2 Market Restraints
4.2.3 Market Opportunity
4.3 Rivaroxaban API Market - Supply Chain Analysis
4.3.1 List of Key Suppliers
4.3.2 List of Key Distributors
4.3.3 List of Key Consumers
4.4 Key Forces Shaping the Rivaroxaban API Market
4.4.1 Bargaining Power of Suppliers
4.4.2 Bargaining Power of Buyers
4.4.3 Threat of Substitution
4.4.4 Threat of New Entrants
4.4.5 Competitive Rivalry
4.5 Global Rivaroxaban API Market Size & Forecast, 2018-2028
4.5.1 Rivaroxaban API Market Size and Y-o-Y Growth
4.5.2 Rivaroxaban API Market Absolute $ Opportunity
Chapter 5 Global Rivaroxaban API Market Analysis and Forecast by Type
5.1 Introduction
5.1.1 Key Market Trends & Growth Opportunities by Type
5.1.2 Basis Point Share (BPS) Analysis by Type
5.1.3 Absolute $ Opportunity Assessment by Type
5.2 Rivaroxaban API Market Size Forecast by Type
5.2.1 Purity≥98%
5.2.2 Purity<98%
5.3 Market Attractiveness Analysis by Type
Chapter 6 Global Rivaroxaban API Market Analysis and Forecast by Applications
6.1 Introduction
6.1.1 Key Market Trends & Growth Opportunities by Applications
6.1.2 Basis Point Share (BPS) Analysis by Applications
6.1.3 Absolute $ Opportunity Assessment by Applications
6.2 Rivaroxaban API Market Size Forecast by Applications
6.2.1 Rivaroxaban Tablets
6.2.2 Others
6.3 Market Attractiveness Analysis by Applications
Chapter 7 Global Rivaroxaban API Market Analysis and Forecast by Region
7.1 Introduction
7.1.1 Key Market Trends & Growth Opportunities by Region
7.1.2 Basis Point Share (BPS) Analysis by Region
7.1.3 Absolute $ Opportunity Assessment by Region
7.2 Rivaroxaban API Market Size Forecast by Region
7.2.1 North America
7.2.2 Europe
7.2.3 Asia Pacific
7.2.4 Latin America
7.2.5 Middle East & Africa (MEA)
7.3 Market Attractiveness Analysis by Region
Chapter 8 Coronavirus Disease (COVID-19) Impact
8.1 Introduction
8.2 Current & Future Impact Analysis
8.3 Economic Impact Analysis
8.4 Government Policies
8.5 Investment Scenario
Chapter 9 North America Rivaroxaban API Analysis and Forecast
9.1 Introduction
9.2 North America Rivaroxaban API Market Size Forecast by Country
9.2.1 U.S.
9.2.2 Canada
9.3 Basis Point Share (BPS) Analysis by Country
9.4 Absolute $ Opportunity Assessment by Country
9.5 Market Attractiveness Analysis by Country
9.6 North America Rivaroxaban API Market Size Forecast by Type
9.6.1 Purity≥98%
9.6.2 Purity<98%
9.7 Basis Point Share (BPS) Analysis by Type
9.8 Absolute $ Opportunity Assessment by Type
9.9 Market Attractiveness Analysis by Type
9.10 North America Rivaroxaban API Market Size Forecast by Applications
9.10.1 Rivaroxaban Tablets
9.10.2 Others
9.11 Basis Point Share (BPS) Analysis by Applications
9.12 Absolute $ Opportunity Assessment by Applications
9.13 Market Attractiveness Analysis by Applications
Chapter 10 Europe Rivaroxaban API Analysis and Forecast
10.1 Introduction
10.2 Europe Rivaroxaban API Market Size Forecast by Country
10.2.1 Germany
10.2.2 France
10.2.3 Italy
10.2.4 U.K.
10.2.5 Spain
10.2.6 Russia
10.2.7 Rest of Europe
10.3 Basis Point Share (BPS) Analysis by Country
10.4 Absolute $ Opportunity Assessment by Country
10.5 Market Attractiveness Analysis by Country
10.6 Europe Rivaroxaban API Market Size Forecast by Type
10.6.1 Purity≥98%
10.6.2 Purity<98%
10.7 Basis Point Share (BPS) Analysis by Type
10.8 Absolute $ Opportunity Assessment by Type
10.9 Market Attractiveness Analysis by Type
10.10 Europe Rivaroxaban API Market Size Forecast by Applications
10.10.1 Rivaroxaban Tablets
10.10.2 Others
10.11 Basis Point Share (BPS) Analysis by Applications
10.12 Absolute $ Opportunity Assessment by Applications
10.13 Market Attractiveness Analysis by Applications
Chapter 11 Asia Pacific Rivaroxaban API Analysis and Forecast
11.1 Introduction
11.2 Asia Pacific Rivaroxaban API Market Size Forecast by Country
11.2.1 China
11.2.2 Japan
11.2.3 South Korea
11.2.4 India
11.2.5 Australia
11.2.6 South East Asia (SEA)
11.2.7 Rest of Asia Pacific (APAC)
11.3 Basis Point Share (BPS) Analysis by Country
11.4 Absolute $ Opportunity Assessment by Country
11.5 Market Attractiveness Analysis by Country
11.6 Asia Pacific Rivaroxaban API Market Size Forecast by Type
11.6.1 Purity≥98%
11.6.2 Purity<98%
11.7 Basis Point Share (BPS) Analysis by Type
11.8 Absolute $ Opportunity Assessment by Type
11.9 Market Attractiveness Analysis by Type
11.10 Asia Pacific Rivaroxaban API Market Size Forecast by Applications
11.10.1 Rivaroxaban Tablets
11.10.2 Others
11.11 Basis Point Share (BPS) Analysis by Applications
11.12 Absolute $ Opportunity Assessment by Applications
11.13 Market Attractiveness Analysis by Applications
Chapter 12 Latin America Rivaroxaban API Analysis and Forecast
12.1 Introduction
12.2 Latin America Rivaroxaban API Market Size Forecast by Country
12.2.1 Brazil
12.2.2 Mexico
12.2.3 Rest of Latin America (LATAM)
12.3 Basis Point Share (BPS) Analysis by Country
12.4 Absolute $ Opportunity Assessment by Country
12.5 Market Attractiveness Analysis by Country
12.6 Latin America Rivaroxaban API Market Size Forecast by Type
12.6.1 Purity≥98%
12.6.2 Purity<98%
12.7 Basis Point Share (BPS) Analysis by Type
12.8 Absolute $ Opportunity Assessment by Type
12.9 Market Attractiveness Analysis by Type
12.10 Latin America Rivaroxaban API Market Size Forecast by Applications
12.10.1 Rivaroxaban Tablets
12.10.2 Others
12.11 Basis Point Share (BPS) Analysis by Applications
12.12 Absolute $ Opportunity Assessment by Applications
12.13 Market Attractiveness Analysis by Applications
Chapter 13 Middle East & Africa (MEA) Rivaroxaban API Analysis and Forecast
13.1 Introduction
13.2 Middle East & Africa (MEA) Rivaroxaban API Market Size Forecast by Country
13.2.1 Saudi Arabia
13.2.2 South Africa
13.2.3 UAE
13.2.4 Rest of Middle East & Africa (MEA)
13.3 Basis Point Share (BPS) Analysis by Country
13.4 Absolute $ Opportunity Assessment by Country
13.5 Market Attractiveness Analysis by Country
13.6 Middle East & Africa (MEA) Rivaroxaban API Market Size Forecast by Type
13.6.1 Purity≥98%
13.6.2 Purity<98%
13.7 Basis Point Share (BPS) Analysis by Type
13.8 Absolute $ Opportunity Assessment by Type
13.9 Market Attractiveness Analysis by Type
13.10 Middle East & Africa (MEA) Rivaroxaban API Market Size Forecast by Applications
13.10.1 Rivaroxaban Tablets
13.10.2 Others
13.11 Basis Point Share (BPS) Analysis by Applications
13.12 Absolute $ Opportunity Assessment by Applications
13.13 Market Attractiveness Analysis by Applications
Chapter 14 Competition Landscape
14.1 Rivaroxaban API Market: Competitive Dashboard
14.2 Global Rivaroxaban API Market: Market Share Analysis, 2019
14.3 Company Profiles (Details – Overview, Financials, Developments, Strategy)
14.3.1 Dr. Reddy's Laboratories
14.3.2 Actis Generics Pvt Ltd.
14.3.3 ZCL Chemicals Limited
14.3.4 Medichem S.A
14.3.5 UQUIFA
14.3.6 Inke
14.3.7 Teva Pharmaceutical Industries Ltd.
14.3.8 Zhejiang Huahai Pharmaceutial. Co., Ltd.
14.3.9 Morepen Labs
14.3.10 Shaanxi Hanjiang Pharmaceutical
14.3.11 Jiangsu Jiayi
14.3.12 Shanghai Haoyuan
14.3.13 Nanjing Hicin
